Seer Inc Asset Resilience Ratio
Seer Inc asset resilience ratio. Seer Inc (SEER) has an Asset Resilience Ratio of 49.40% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Seer Inc (SEER) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Seer Inc (2018–2025)
Asset resilience ratio of Seer Inc from 2018 to 2025. This chart shows how Seer Inc's Asset Resilience Ratio has changed over time. Read SEER total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Seer Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Seer Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $126.78 Million | 49.4% |
| Total Liquid Assets | $126.78 Million | 49.40% |
Asset Resilience Insights
- Very High Liquidity: Seer Inc maintains exceptional liquid asset reserves at 49.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Seer Inc Industry Peers by Asset Resilience Ratio
Compare Seer Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Seer Inc Asset Resilience Ratio by Year (2018–2025)
Seer Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Seer Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.82% | $138.61 Million | $296.08 Million | -6.56pp |
| 2024-12-31 | 53.37% | $195.66 Million | $366.60 Million | -11.66pp |
| 2023-12-31 | 65.03% | $283.73 Million | $436.27 Million | -10.39pp |
| 2022-12-31 | 75.43% | $368.03 Million | $487.93 Million | +44.40pp |
| 2021-12-31 | 31.02% | $167.26 Million | $539.14 Million | +8.80pp |
| 2020-12-31 | 22.22% | $98.28 Million | $442.32 Million | -51.29pp |
| 2019-12-31 | 73.51% | $68.53 Million | $93.24 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $33.70 Million | -- |
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis … Read more